Month: March 2021

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.57260-71-6,tert-Butyl piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.,57260-71-6

To a stirred solution of N-Boc piperazine (1 g) in dry THF (20 ml), triethylamine (3 ml), followed by chloroacetonitrile (5.02 ml) were added dropwise. The reaction mixture was allowed to stir at room temperature for overnight. The solvent was removed under vacuum and residue was diluted ethyl acetate (20 ml). The organic layer was concentrated to dryness under reduced pressure to afford tert-butyl 4-(cyanomethyl)piperazine-1-carboxylate, which was used for the next reaction without further purification.1H NMR (400 MHz, CDCl3): delta 1.47 (s, 9H), 2.55 (t, 4H, J=6 Hz), 3.49 (t, 4H, J=4 Hz), 3.55 (s, 2H).GC MS: 225

As the paragraph descriping shows that 57260-71-6 is playing an increasingly important role.

Reference£º
Patent; Bristol-Myers Squibb Company; US2007/249579; (2007); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170911-92-9,tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

mCPBA (<77% pure) (15.6 mg, assumed 0.0693 mmol) in DCM (0.5 mL) was added to a stirred solution of 6- (2 , 6 -dichlorophenyl ) -2- (methylthio) - 8 - (pyridin-3 -yl ) pyrido [4 , 3 -d] pyrimidin-5 ( 6H) -one (25.0 mg, 0.060 mmol) in toluene (2.0 mL) at RT under nitrogen. After 15 min, DIPEA (0.032 mL, 0.181 mmol) and tert-butyl 4-(4- aminophenyl) piperazine-l-carboxylate (16.7 mg, 0.060 mmol) [commercially available] were added, successively, and the temperature was increased to 60 C. After 16 h, the reaction mixture was cooled and loaded directly onto a KP-NH column and purified by flash chromatography (0-100%, EtOAc in cyclohexane) to give the title compound (15.5 mg, 40%) as a yellow solid. LCMS (Method A) : RT = 1.40 min, m/z = 644, 646 [M+H]+. 170911-92-9, The synthetic route of 170911-92-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ALMAC DISCOVERY LIMITED; O’DOWD, Colin Roderick; ROUNTREE, James Samuel Shane; BURKAMP, Frank; WILKINSON, Andrew John; WO2014/167347; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.639068-43-2,tert-Butyl 3,5-dimethylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.,639068-43-2

General procedure: Add to 100mL three-necked bottle under argon protectiontert-Butyl 3,5-dimethylpiperazine-1-carboxylate (520 mg, 2.43 mmol) and THF (10 mL), cooled to about 0 ¡ã C,Add NaH (70 mg, 2.91 mmol),After stirring for half an hour, a solution of CH3I (690 mg, 4.86 mmol) in THF (1 mL) was added dropwise.After the dropwise addition, the mixture was stirred for 1 hour, and the reaction was further stirred up to room temperature. The reaction was monitored by TLC. After the reaction was completed, 50 mL of purified water and 30 mL of ethyl acetate were added, and the mixture was stirred. The aqueous phase was extracted twice with ethyl acetate (30 mL¡Á2), and the organic phase was combined and washed with saturated brine (50 mL¡Á2) After 2 times, anhydrous sodium sulfate was dried, filtered, and the mother liquid was concentrated under reduced pressure to give 510 mg of product.

The synthetic route of 639068-43-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Beijing Purunao Bio-technology Co., Ltd.; Zhang Peilong; Shi Hepeng; Lan Wenli; Song Zhitao; (250 pag.)CN108707139; (2018); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.39539-66-7,4-Methylpiperazine-1-carbonyl chloride,as a common compound, the synthetic route is as follows.

Example 8 N- [3,3-Dimethyl -1- (4-methyl-piperazine-1-carbonyl) -2, 3- [ DIHYDRO-LH-INDOL-6-YL]-2- (4-FLUORO-BENZYLAMINO)-BENZAMIDE] Step A: Preparation of [N- [3, 3-DIMETHYL-L- (4-METHYL-] [PIPERAZINE-1-CARBONYL)-2, 3-DIHYDRO-LH-INDOL-6-YL]-2-NITRO-] benzamide [N- (3,] 3-dimethyl-2, [3-DIHYDRO-LH-INDOL-6-YL)-2-NITRO-] benzamide (Example 7, Step A) (300 mg, 0.96 mmol) was treated with [4-METHYL-PIPERAZINE-1-CARBONYL] chloride (200 mg, 1 mmol) in the presence of DIEA (40 mL) in THF overnight at 65 [C.] The mixture was partitioned between EtOAc and saturated aqueous [NAHC03.] The organic layer was washed with [H2O] and brine, then dried over [NA2SO4.] The organic solution was concentrated in vacuo to yield the desired compound., 39539-66-7

The synthetic route of 39539-66-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; AMGEN INC.; WO2004/5279; (2004); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

103-76-4, N-(2-Hydroxyethyl)piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 1-(2-hydroxyethyl)piperazine (651 mg, 5.00 mmol, 1.0 equiv.) in anhydrous tetrahydrofuran (15 mL) was added, at 000 under argon and dropwise, carbon disulfide (452 pL, 7.50 mmol, 1.5 equiv.). After 15 mm of stirring at 0C, sodium hydride (60% dispersion in mineral oil) (200 mg, 5.00 mmol, 1.0 equiv.) was added portionwise. After 40 mm of stirring at0C, the reaction mixture was concentrated in vacuo. The resulting crude product was washed several times with cyclohexane to eliminate mineral oil and then concentrated in vacuo et dried with a vane pump during one night to afford compound A083 (1.10 g, 4,82 mmol) as a pale yellow powder in 96 % yield which was used in the next step without further purification. 1H NMR (400 MHz, MeOD) 5 4.46 (t, J = 4.8 Hz, 4H, CH2N), 3.71 (t, J = 5.9 Hz,2H, CH2O), 2.55 (t, J = 5.1 Hz, 6H, CH2N). 130 NMR (100 MHz, MeOD) 5 60.98 (CH2N),59.80 (CH2O), 54.35 (CH2N), 51.20 (CH2N).

103-76-4, The synthetic route of 103-76-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UNIVERSITE PARIS EST CRETEIL VAL DE MARNE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); MOTTERLINI, Roberto; FORESTI, Roberta; MARTENS, Thierry; RIVARD, Michael; WO2015/140337; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

4318-42-7,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4318-42-7,1-Isopropylpiperazine,as a common compound, the synthetic route is as follows.

EXAMPLES; Intermediate 1; (1H-Indol-5-yl)-(4-isopropyl-piperazin-1-yl)-methanone; A mixture of 3.23 g (20 mmol) indole-5-caboxylic acid (commercially available), 3.07 g (24 mmol) 1-(2-propyl)-piperazine (commercially available), 8.03 g (25 mmol) TBTU and 10.3 mL (60 mmol) DIPEA in 50 mL DMF was stirred for 2 h at room temperature. After evaporation of all volatiles the residue was extracted with ethyl acetate, the combined organic layers dried with MgSO4 and evaporated to dryness. The residue was subsequently purified by flash column chromatography eluting with a mixture formed from DCM, MeOH and NH3 aq. to yield after evaporation of the combined product fractions 5.1 g (94percent) of the title compound as light brown foam. MS (m/e): 272.3 (MH+).

4318-42-7 1-Isopropylpiperazine 78013, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Nettekoven, Matthias; Roche, Olivier; US2008/188486; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

13754-38-6, 1-Benzoylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Manufacturing example 9: (4-(2-hydroxy-2-methylpropyl)piperazine-1-yl)phenylmethanon e [Show Image] 500 mg (2.63 mmol) 1-benzoylpiperazine and 1.10 g (7.96 mmol, 3.0 eq.) potassium carbonate were suspended to 20 ml acetonitrile at room temperature. After adding 570 mg (7.90 mmol, 3.0 eq.) isobutylene oxide, it was heated at reflux and stirred overnight. After cooling to room temperature and adding 30 ml purified water, it was extracted twice with 30 ml ethylacetate. After collecting the organic layer and drying with anhydrous magnesium sulfate, it was concentrated with decompression. The obtained residue was purified by chromatography using silicagel (mobile phase: dichloromethane/methanol= 20:1) and 276 mg (40%) target compound as light-yellow solid were yielded. 1HNMR(400MHz,DMSO-d6) 1.10(6H,s), 2.23(2H,s), 2.43-2.52(2H,m), 2.53-2.62(2H,m), 3.35-3.45(2H,m), 3.55-3.65(2H,m), 4.13(1H,s), 7.35-7.38(2H,m), 7.43-7.46(3H,m), 13754-38-6

The synthetic route of 13754-38-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Yang Ji Chemical Co., Ltd.; EP2452939; (2012); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21655-48-1,cis-2,6-Dimethylpiperazine,as a common compound, the synthetic route is as follows.

Step 1: 3,5-Dimethyl-l-(4-trifluoromethoxy-bepizyl)-piperazine: To a solution of 4-(trifluoromethoxy)- benzaldehyde (776 muL, 4.38 mmol) in dichloromethane (30 mL) was added 2,6-dimethy. piperazine (1.0 g, 8.77mmol). The reaction mixture was stirred for Ih. Sodium triacetoxy borohydride (2.45 g, 8.77 mmol) was added and the reaction mixture was stirred for 4h. The reaction mixture was concentrated in vacuo, diluted with ethyl acetate and extracted with IN HCl (2 x 50 mL). The combined aqueous solution was neutralized with NaOH and extracted with ethyl acetate (3 x 50 mL). The combined organic solution was dried (Ts^SO,)) and concentrated in vacuo to provide 3,5-dimethyl-l-(4- trifluoromethoxy-benzyl)-piperazine (1.01 g, 80percent) as a clear oil. 1H NMR (400 MHz, CD3OD) delta 7.42 (d, 2H), 7.23 (d, 2H), 3.54 (s, 2H), 2.98-2.88 (m, 2H), 2.82-2.74,(m, 2H), 1.69 (t, 2H), 1.05 (d,6H); LCMS 289.5 (M+l)+.

21655-48-1, 21655-48-1 cis-2,6-Dimethylpiperazine 6950261, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; KALYPSYS, INC.; WO2007/47431; (2007); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.889958-14-9,1-Boc-2-oxopiperazine,as a common compound, the synthetic route is as follows.

EXAMPLE 25 t-Butyl 3-oxo-2-benzylidenyl-1-piperazinecarboxylate (25) To a solution of diisopropylamine (0.31 ml, 2.2 mmole) and dry THF (2 ml) at 0 C. under argon is added dropwise a hexane solution of n-butyllithium (0.90 ml, 2.2 mmole). After 1/2 hour, a solution of 2 (0.200 g, 1.00 mmole) in dry THF is added dropwise and stirred at 0 C. for 3 hours, and benzaldehyde (0.11 ml, 1.1 mmole) added dropwise. The reaction is stirred for 1 hour, the cooling bath is removed and the reaction stirred for an additional 2 hours. Acetyl chloride (0.078 ml, 1.1 mmole) was added and the mixture stirred overnight, quenched into ether/water, and purified as described in Example 23. Chromatography on silica gel with 10% methanol/chloroform yields colorless solid 25. M.p. 191-193 C.

889958-14-9, As the paragraph descriping shows that 889958-14-9 is playing an increasingly important role.

Reference£º
Patent; Richardson-Merrell Inc.; US4341698; (1982); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.54699-92-2,4-Methyl-1-piperazineacetic acid,as a common compound, the synthetic route is as follows.

A solution of (1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-(hydroxymethyl)benzoate (1.104 g, 1.63 mmol) obtained from Example 17-(4) in dichloromethane (25 ml) was cooled to 0C, and then 4-(N,N-dimethylamino)pyridine (299.1 mg, 2.45 mmol), 2-(4-methyl-1-piperazinyl)acetic acid (described in J. Med. Chem., 43, 1493 (2000); 387.3 mg, 2.45 mmol), and 1-ethyl-3-[3-(N,N-dimethylamino)propyl]carbodiimide (625.5 mg, 3.26 mmol) were added thereto. The reaction solution was stirred at room temperature for 4 hours, diluted with dichloromethane, and then the organic layer was washed successively with water and a saturated aqueous solution of sodium chloride. The solvent was evaporated under reduced pressure, and the residue was subjected to chromatography on a silica gel (40 g) column (eluent; ethyl acetate : methanol = 4 : 1) to give a mixture of the title target compound and 4-(N,N-dimethylamino)pyridine. The mixture was purified by recycle preparative HPLC [LC-908; Japan Analytical Industry Co., Ltd.; GPC column JAIGEL-1H (20 mm i.d. x 600 mm) and JAIGEL-2H (20 mm i.d. x 600 mm) connected in series for use; solvent, chloroform] to afford the title target compound (865.2 mg, 65% yield) as a colorless amorphous solid. NMR spectrum (400 MHz, CDCl3) delta ppm: 1.46 (3H, dd, J=7, 2 Hz), 2.29 (3H, s), 2.4-2.5 (4H, br s), 2.6-2.7 (4H, br s), 3.05 (1H, tt, J=12, 5 Hz), 3.31 (2H, s), 3.50 (1H, t, J=12 Hz), 3.53 (1H, t, J=12 Hz), 4.01 (1H, q, J=7 Hz), 4.12-4.21 (2H, m), 4 99 (1H, d, J=4 Hz), 5.45-5.55 (4H, m), 5.84 (1H, dd, J=15, 4 Hz), 6.57 (1H, dd, J=15, 10 Hz), 6.73 (1H, d, J=16 Hz), 6.93 (1H, dd, J=16, 10 Hz), 6.88-7.00 (2H, m), 7.34 (1H, dd, J=11, 1 Hz), 7.27-7.46 (3H, m), 7.53-7.60 (3H, m), 7.79 (1H, dd, J=8, 1 Hz), 7.90 (1H, s), 7.95 (1H, s) IR spectrum nu max KBr cm-1: 2230, 1726, 1503, 1275, 1257, 1051, 1140, 973 Mass spectrum m/z (FAB): 817 (M++1) Specific rotation [alpha]D25 +0.4 (c=0.99, CHCl3). A solution of (1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-[[2-(4-methylpiperazin-1-yl)acetoxy]methyl]benzoate (280 mg, 0.343 mmol) obtained above in ethyl acetate (5 ml) was cooled to 0C, and hydrogen chloride (4N ethyl acetate solution; 95 mul, 0.38 mmol) was added thereto, and the mixture was stirred at 0C for 5 minutes. The solvent was evaporated under reduced pressure, and the residue was dried in vacuo to afford the mono hydrochloric acid salt of the title compound (298 mg, quantitative yield) as a pale yellow amorphous solid. NMR spectrum (400 MHz, CD3OD) delta ppm: 1.43 (3H, dd, J=7, 1 Hz), 2.87 (3H, s), 2.8-3.4 (8H, br), 3.04 (1H, tt, J=11, 5 Hz), 3.48 (1H, t, J=11 Hz), 3.53 (2H, s), 3.54 (1H, t, J=11 Hz), 4.06 (1H, q, J=7 Hz), 4.04-4.08 (2H, m), 4.17 (1H, ddd, J=11, 5, 2 Hz), 5.20 (1H, d, J=4 Hz), 5.46 (1H, d, J=14 Hz), 5.53 (1H, d, J=14 Hz), 5.58 (2H, s), 5.85 (1H, dd, J=15, 4 Hz), 6.57 (1H, dd, J=15, 10 Hz), 6.79 (1H, d, J=16 Hz), 7.01-7.11 (2H, m), 7.09 (1H, dd, J=16, 10 Hz), 7.46 (1H, td, J=8, 1 Hz), 7.50-7.61 (3H, m), 7.63 (1H, qd, J=7, 1 Hz), 7.78 (1H, t, J=8 Hz), 7.86 (1H, dd, J=7, 1 Hz), 7.95 (1H, s), 8.34 (1H, s) IR spectrum nu max KBr cm-1: 2230, 1726, 1503, 1274, 1257, 1140, 1050, 973 Mass spectrum m/z (FAB): 817 [M+(free base)+1] Specific rotation [alpha]D25 -1.9 (c=0.97, CHCl3). A solution of (1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-[[2-(4-methylpiperazin-1-yl)acetoxy]methyl]benzoate (338.5 mg, 0.41 mmol) obtained above in ethyl acetate (5 ml) was cooled to 0C, and hydrogen chloride (4N ethyl acetate solution; 207 mul, 0.83 mmol) was added thereto, and the mixture was stirred at 0C for 5 minutes. The solvent was evaporated under reduced pressure, and the residue was dried in vacuo to afford the bis hydrochloric acid salt of the title compound (354 mg, quantitative yield) as a pale yellow amorphous solid. NMR spectrum (400 MHz, DMSO-d6) delta ppm: 1.35 (3H, dd, J=7, 2 Hz), 2.76 (3H, s), 2.82-2.92 (2H, br), 2.99 (1H, tt, J=11, 5 Hz), 3.06-3.16 (4H, br), 3.41 (2H, br d, J=15 Hz), 3.46 (1H, t, J=11 Hz), 3.47 (1H, t, J=11 Hz), 3.65 -3.75 (2H, br), 3.79 (1H, q, J=7 Hz), 3.96 (1H, ddd, J=11, 5, 2 Hz), 4.07 (1H, ddd, J=11, 5, 2 Hz), 5.05 (1H, d, J=5 Hz), 5.39 (1H, d, J=13 Hz), 5.40 (1H, d, J=14 Hz), 5.49 (1H, d, J=13 Hz), 5.56 (1H, d, J=14 Hz), 5.88 (1H, dd, J=15, 5 Hz), 6.56 (1H, dd, J=15, 11 Hz), 6.82 (1H, d, J=16 Hz), 7.16-7.20 (1H, m), 7.19 (1H, dd, J=16, 11 Hz), 7.31-7.37 (1H, m), 7.49-7.55 (1H, m), 7.55 (1H, td, J=9, 6 Hz), 7.60 (1H, d, J=7 Hz), 7.67-7.71 (2H, m), 7.84-7.89 (3H, m), 7.96 (1H, s), 8.44 (1H, s) Mass spectrum m/z (FAB): 817 [M+(free base)+1] Specific rotation [alpha]D25 -3.1 (c=1.87, CHCl3), 54699-92-2

The synthetic route of 54699-92-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Sankyo Company, Limited; EP1362856; (2003); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics